Soleno Therapeutics Earnings Call Highlights Surging Launch

Soleno Therapeutics ((SLNO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Soleno Therapeutics’ latest earnings call struck an upbeat tone as management highlighted a powerful U.S. launch, sharply improving financials and a solid cash runway. Executives balanced that optimism with frank discussion of EU regulatory uncertainty, rising costs and expected patient discontinuation, but the overall narrative pointed to durable commercial momentum.

Explosive Revenue Growth and a Swift Move to Profitability

Soleno reported Q4 net revenue of $91.7 million, up nearly 40% from $66.0 million in Q3, despite having fewer than nine months of commercial sales in 2025. Full‑year net revenue reached $190.4 million and net income came in at $20.9 million, with Q4 alone delivering roughly $43.4 million in profit versus losses a year ago.

Cash Generation and Balance Sheet Strength Bolster Flexibility

The launch is already throwing off cash, with $48.7 million generated from operating activities in Q4. The company ended the year holding $506.1 million in cash, cash equivalents and marketable securities, even after a $100 million accelerated share repurchase, giving it ample capital for U.S. growth, EU work and pipeline expansion.

Commercial Launch Metrics Signal Deepening Market Penetration

Since launch through December 31, the company received 1,250 patient start forms, amounting to roughly 12.5% of its estimated U.S. addressable market. Active patients on therapy climbed to 859, up from 764 at the end of Q3, marking a quarter‑over‑quarter increase of about 12.4% as uptake broadened.

Prescriber Adoption Expands Across the U.S. Market

Prescriber engagement also strengthened, with 136 new physicians added during Q4, bringing the total to 630 unique prescribers. This widening base of treating clinicians suggests growing comfort with the product and supports expectations for continued patient onboarding in 2026.

Broad Payer Coverage Underpins Access and Reimbursement

On the access front, Soleno has secured coverage across commercial plans, Medicaid and Medicare, collectively representing more than 180 million covered lives. The company also reported reimbursed claims from roughly 45 state Medicaid programs by year‑end, helping support rapid access and favorable reauthorizations.

Real‑World Safety, Adherence and Discontinuation Trends

Management said the real‑world safety profile is in line with clinical trial experience, with adverse‑event‑related discontinuations of about 12% since launch. Total discontinuation sits near 15%, which is consistent with the company’s expected long‑term range of 15% to 20%, while adherence remains high as patients settle into optimized dosing.

Pipeline Expansion: EU Push and GSD1 Opportunity

Beyond the core indication, the firm is pursuing EU approval, with its marketing application validated by the EMA and Day‑120 questions already answered, while Day‑180 feedback is expected soon. Soleno is also advancing a program in glycogen storage disease type 1, which holds orphan status in the U.S. and EU, with an IND targeted for the first half of 2026 and a trial start later that year.

EU Regulatory Uncertainty Clouds Ex‑U.S. Trajectory

Despite the progress, management emphasized that EMA reviewers are focused on whether efficacy data from the randomized withdrawal study are sufficient. With Day‑180 questions imminent and a final decision not expected until mid‑2026, the outcome of the EU process remains uncertain and may temper near‑term ex‑U.S. expansion plans.

Seasonal and Gross‑to‑Net Headwinds Expected in Q1

Investors were cautioned that first‑quarter revenue may not fully reflect underlying patient growth because of seasonal dynamics. Co‑pay resets, plan churn and temporary free‑drug periods, particularly as Soleno’s co‑pay assistance program reimburses patients, can inflate gross‑to‑net discounts and pressure reported Q1 revenue.

Rising Commercial Spend and Launch‑Driven SG&A

The aggressive rollout is showing up in operating expenses, with full‑year SG&A rising to $132.1 million from $105.9 million, an increase of roughly 24.7%. Q4 SG&A reached $40.9 million, including $8.7 million of stock‑based compensation, and management signaled that commercialization investments will keep SG&A elevated near term.

COGS Set to Normalize as Zero‑Cost Inventory Rolls Off

Reported cost of goods sold remained unusually low, at $0.9 million in Q4 and $2.7 million for the year, aided by pre‑approval inventory that had been expensed to R&D at zero cost. Executives warned that as this inventory is depleted and replaced with at‑cost product, COGS as a percentage of revenue should rise toward mid‑single‑digit gross cost levels.

Adherence and Discontinuation Risk to Long‑Term Penetration

While current discontinuation levels are within expectations, management acknowledged that a sustained 15% to 20% long‑term rate could influence market penetration and revenue durability. The company is closely monitoring adherence patterns to ensure patients remain on therapy and realize full clinical benefit over time.

Planned Reduction in KPI Transparency After 2026

Soleno plans to keep reporting key launch metrics, including patient start forms, prescriber counts and covered lives, through the Q1 2026 call. After providing a 12‑month KPI update then, it intends to retire these disclosures, which could limit investors’ visibility into ongoing launch performance beyond that point.

Forward‑Looking Guidance and Strategic Outlook

Management framed the current trajectory as a “strong ongoing launch,” anchored by $91.7 million of Q4 revenue, robust Q4 cash from operations of $48.7 million and year‑end cash of $506.1 million after share repurchases. They expect to capture roughly 1,000 additional patient start forms over the next nine to twelve months while guiding to a long‑term discontinuation rate of 15% to 20% and rising COGS as inventory normalizes.

Soleno’s earnings call painted the picture of a rare‑disease launch that is exceeding early expectations, backed by strong revenue growth, profitability and substantial cash reserves. While EU regulatory risks, rising costs and adherence dynamics warrant monitoring, the company’s momentum in the U.S. and expanding pipeline suggest a compelling, if still evolving, growth story for investors.